Most people regain a significant portion of lost weight after stopping semaglutide. A 2022 study published in Diabetes, Obesity and Metabolism found that participants regained approximately two-thirds of their lost weight within one year of discontinuing the medication — and most cardiometabolic improvements reversed as well.
What Did the Study Actually Find?
The landmark STEP 1 trial extension, led by Wilding et al. and published in Diabetes, Obesity and Metabolism (2022), tracked 327 adults for one year after they stopped taking 2.4 mg semaglutide (Wegovy). Key findings included:
- Participants had lost an average of 17.3% of body weight during 68 weeks on semaglutide.
- One year after stopping, they had regained an average of 11.6 percentage points of that loss — roughly two-thirds of the total weight lost.
- By the end of the follow-up period, net weight loss from original baseline was only about 5.6%.
- Improvements in waist circumference, blood pressure, blood sugar, and cholesterol largely reversed alongside the weight regain.
Importantly, the study population stopped semaglutide abruptly and received no replacement medication, which represents a real-world scenario many people face when they discontinue due to cost, supply, or side effects.
The most important takeaway: Semaglutide works by suppressing appetite through GLP-1 receptor pathways that remain active only while you take the drug. Once you stop, those hunger-regulating signals return to baseline — which is why weight regain is the rule, not the exception, according to the Wilding et al. 2022 study.
What Does the Week-by-Week Regain Timeline Look Like?
The STEP 1 extension study tracked participants at several points during the 52-week post-treatment period. The table below summarizes the approximate weight trajectory observed in that research.
| Timepoint | Approximate Weight Change from End-of-Treatment | Net Loss vs. Original Baseline |
|---|---|---|
| Week 0 (last dose) | — | –17.3% |
| Weeks 1–4 | Regain begins; appetite returns | ~–15% |
| Week 20 | +6–7% from end-of-treatment weight | ~–10% |
| Week 52 (1 year) | +11.6% from end-of-treatment weight | ~–5.6% |
Regain was fastest in the first 20 weeks, then slowed. Researchers noted that weight had not fully returned to pre-treatment levels by week 52, suggesting the body may stabilize at a slightly lower set point — but well above the treatment nadir.
Why Does Weight Come Back After Stopping Semaglutide?
This is not a willpower problem. Obesity is recognized by the NIH and major medical organizations as a chronic, relapsing disease with strong biological drivers. Semaglutide works by mimicking the GLP-1 hormone, which signals fullness to the brain, slows gastric emptying, and reduces food cravings. When the drug is removed:
- Hunger hormones rebound. Ghrelin and other appetite signals return to pre-treatment levels.
- Metabolic rate adjustments persist. The body's adaptive response to weight loss — lowering its calorie-burning baseline — doesn't immediately reverse.
- Food noise returns. Many patients report that intrusive thoughts about food, quieted during treatment, come back quickly after stopping.
The Wilding et al. authors explicitly concluded that their findings "confirm the need for ongoing treatment to maintain improvements in weight and cardiometabolic risk factors."
Does Everyone Regain the Same Amount?
No. Individual responses vary based on several factors, though the study did not identify one single predictor of who regains more or less. Factors that may influence post-discontinuation outcomes include:
- Duration of treatment: Longer treatment periods may allow more lifestyle habits to become entrenched, potentially supporting partial weight maintenance.
- Behavioral interventions: Participants in the STEP trials received counseling on diet and physical activity. Those who continued those behaviors after stopping fared somewhat better.
- Reason for stopping: People who stopped due to side effects versus cost versus reaching a goal may have different motivational contexts that influence what happens next.
- Comorbidities: Individuals with type 2 diabetes using Ozempic (the lower-dose 0.5–2 mg version) may have additional medical reasons to continue, and their prescribers may be more likely to maintain treatment.
What Are the Options If You Have to Stop?
If you must stop semaglutide — due to cost, shortage, pregnancy, or another reason — there are evidence-informed strategies worth discussing with your prescriber:
- Structured calorie monitoring: Without appetite suppression from the drug, tracking intake becomes more important.
- Increased physical activity: Exercise helps offset some metabolic slowdown associated with weight loss maintenance.
- Transition to another medication: A prescriber may consider switching to a different agent, such as tirzepatide (Mounjaro/Zepbound), metformin, or an SSRI-adjacent option like bupropion/naltrexone, depending on your health profile.
- Tapering vs. abrupt stop: There is currently no published evidence that tapering semaglutide reduces rebound, but some clinicians recommend it to allow gradual appetite adjustment. Ask your prescriber what they recommend.
- Restarting when possible: The same STEP 1 extension authors noted that restarting semaglutide after a break appeared to restore weight-loss response, suggesting the medication does not lose effectiveness with interruption.
Frequently Asked Questions
Weight regain after stopping semaglutide is a well-documented, biology-driven outcome — not a reflection of effort or discipline. If you are considering stopping Wegovy or Ozempic, or have already stopped and are noticing regain, talk with your prescriber. They can help you weigh the risks and benefits of continuing, switching medications, or building a maintenance plan tailored to your health goals.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- FDA Ozempic (semaglutide) Prescribing Information. Novo Nordisk. 2023.
- FDA Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2023.
- Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity. JAMA. 2022;327(2):138-150.
- NIH National Institute of Diabetes and Digestive and Kidney Diseases. Overweight and Obesity Statistics. 2021.